In a small study in a community oncology practice, more than 60% of patients with advanced squamous cell skin cancer treated ...

Deborah S. Sarnoff, M.D., talks about the recent breakthrough treatments that are paving the way to treat patients with ...

Libtayo was the sixth PD-L/PD-L1 inhibitor to reach the market, starting out as a therapy for another skin cancer called cutaneous squamous cell carcinoma (CSCC), and the rarity of that disease ...

The EC approved Libtayo – a fully human monoclonal ... (SCC), advanced basal cell carcinoma (BCC), advanced cutaneous squamous cell carcinoma (CSCC), and advanced non-small cell lung cancer ...

Checkpoint Therapeutics is being acquired by Sun Pharmaceutical for $4.10 per share. Learn why CKPT stockholders could earn ...

which assessed Libtayo's efficacy and safety profile as an adjuvant therapy for high-risk CSCC [cutaneous squamous cell carcinoma]. So, the primary endpoint of this study was disease-free survival.

Libtayo received positive phase 3 trial results in high-risk adjuvant cutaneous squamous cell carcinoma (CSCC).

Opens in a new tab or window SAN FRANCISCO -- A combination of cemiplimab (Libtayo ... for locally advanced or metastatic cutaneous squamous cell carcinoma. EPIC-A included 29 patients who ...

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo ® (cemiplimab ... 78% of patients had squamous cell carcinoma (SCC) and 22% had ...

The trial evaluates THIO's safety, tolerability, and efficacy in combination with PD-(L)1 inhibition. THIO sequenced with Libtayo extended overall survival in those with non–small cell lung cancer who ...